Drug
Lemborexant
Lemborexant: highest development phase Phase 2, developed by Eisai. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lemborexant 10 mg NCT06274528 | Phase 2 | Alzheimer Disease |
| Lemborexant 2.5 mg NCT03001557 | Phase 2 | Irregular Sleep-Wake Rhythm Disorder |
Latest
No recent events.
Follow Lemborexant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.